| Richard P Millman, MD | |
|
1 James P Murphy Ind Hwy, West Warwick, RI 02893-2380 | |
| (401) 615-5878 | |
| (401) 615-5886 |
| Full Name | Richard P Millman |
|---|---|
| Gender | Male |
| Speciality | Sleep Medicine |
| Experience | 48 Years |
| Location | 1 James P Murphy Ind Hwy, West Warwick, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699715813 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RS0012X | Internal Medicine - Sleep Medicine | MD06675 (Rhode Island) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | MD06675 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Rhode Island Hospital | Providence, RI | Hospital |
| The Miriam Hospital | Providence, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Brown Medicine | 0446159776 | 205 |
| The Miriam Hospital | 6901796408 | 186 |
News Archive
Dongsheng Pharmaceutical International Co., Ltd. announced today that it has entered into an agreement with Shanghai Wan'Te Pharmaceutical Co., Ltd. to acquire the intellectual property, exclusive sales and manufacturing rights of micro-emulsion alprostadil injection from Wan'Te for total proceeds of RMB10 million, of which RMB5 million will be paid in cash and RMB5 million will be paid in shares of the Company's common stock.
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas.
Remote Diagnostic Technologies Ltd., an innovator in pre-hospital care, today announced the launch of its Tempus ALS monitor and defibrillator at the Emergency Services Show in Birmingham. Lighter and more focused than existing technologies, the Tempus ALS enables paramedics to carry less and do much more.
HDL is the 'good cholesterol' that helps remove fat from artery walls, reversing the process that leads to heart disease. Yet recent drug trials and genetic studies suggest that simply pushing HDL levels higher doesn't necessarily reduce the risk of heart disease.
› Verified 1 days ago
| Entity Name | Rhode Island Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861420333 PECOS PAC ID: 8921900044 Enrollment ID: O20040121000169 |
News Archive
Dongsheng Pharmaceutical International Co., Ltd. announced today that it has entered into an agreement with Shanghai Wan'Te Pharmaceutical Co., Ltd. to acquire the intellectual property, exclusive sales and manufacturing rights of micro-emulsion alprostadil injection from Wan'Te for total proceeds of RMB10 million, of which RMB5 million will be paid in cash and RMB5 million will be paid in shares of the Company's common stock.
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas.
Remote Diagnostic Technologies Ltd., an innovator in pre-hospital care, today announced the launch of its Tempus ALS monitor and defibrillator at the Emergency Services Show in Birmingham. Lighter and more focused than existing technologies, the Tempus ALS enables paramedics to carry less and do much more.
HDL is the 'good cholesterol' that helps remove fat from artery walls, reversing the process that leads to heart disease. Yet recent drug trials and genetic studies suggest that simply pushing HDL levels higher doesn't necessarily reduce the risk of heart disease.
› Verified 1 days ago
| Entity Name | Brown Medicine |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689626764 PECOS PAC ID: 0446159776 Enrollment ID: O20040219000354 |
News Archive
Dongsheng Pharmaceutical International Co., Ltd. announced today that it has entered into an agreement with Shanghai Wan'Te Pharmaceutical Co., Ltd. to acquire the intellectual property, exclusive sales and manufacturing rights of micro-emulsion alprostadil injection from Wan'Te for total proceeds of RMB10 million, of which RMB5 million will be paid in cash and RMB5 million will be paid in shares of the Company's common stock.
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas.
Remote Diagnostic Technologies Ltd., an innovator in pre-hospital care, today announced the launch of its Tempus ALS monitor and defibrillator at the Emergency Services Show in Birmingham. Lighter and more focused than existing technologies, the Tempus ALS enables paramedics to carry less and do much more.
HDL is the 'good cholesterol' that helps remove fat from artery walls, reversing the process that leads to heart disease. Yet recent drug trials and genetic studies suggest that simply pushing HDL levels higher doesn't necessarily reduce the risk of heart disease.
› Verified 1 days ago
| Entity Name | The Miriam Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770520462 PECOS PAC ID: 6901796408 Enrollment ID: O20040624000947 |
News Archive
Dongsheng Pharmaceutical International Co., Ltd. announced today that it has entered into an agreement with Shanghai Wan'Te Pharmaceutical Co., Ltd. to acquire the intellectual property, exclusive sales and manufacturing rights of micro-emulsion alprostadil injection from Wan'Te for total proceeds of RMB10 million, of which RMB5 million will be paid in cash and RMB5 million will be paid in shares of the Company's common stock.
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas.
Remote Diagnostic Technologies Ltd., an innovator in pre-hospital care, today announced the launch of its Tempus ALS monitor and defibrillator at the Emergency Services Show in Birmingham. Lighter and more focused than existing technologies, the Tempus ALS enables paramedics to carry less and do much more.
HDL is the 'good cholesterol' that helps remove fat from artery walls, reversing the process that leads to heart disease. Yet recent drug trials and genetic studies suggest that simply pushing HDL levels higher doesn't necessarily reduce the risk of heart disease.
› Verified 1 days ago
| Entity Name | Lifespan Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407116643 PECOS PAC ID: 2567455082 Enrollment ID: O20121029000368 |
News Archive
Dongsheng Pharmaceutical International Co., Ltd. announced today that it has entered into an agreement with Shanghai Wan'Te Pharmaceutical Co., Ltd. to acquire the intellectual property, exclusive sales and manufacturing rights of micro-emulsion alprostadil injection from Wan'Te for total proceeds of RMB10 million, of which RMB5 million will be paid in cash and RMB5 million will be paid in shares of the Company's common stock.
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas.
Remote Diagnostic Technologies Ltd., an innovator in pre-hospital care, today announced the launch of its Tempus ALS monitor and defibrillator at the Emergency Services Show in Birmingham. Lighter and more focused than existing technologies, the Tempus ALS enables paramedics to carry less and do much more.
HDL is the 'good cholesterol' that helps remove fat from artery walls, reversing the process that leads to heart disease. Yet recent drug trials and genetic studies suggest that simply pushing HDL levels higher doesn't necessarily reduce the risk of heart disease.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Richard P Millman, MD 17 Virginia Ave, Suite 107, Providence, RI 02905-4406 Ph: () - | Richard P Millman, MD 1 James P Murphy Ind Hwy, West Warwick, RI 02893-2380 Ph: (401) 615-5878 |
News Archive
Dongsheng Pharmaceutical International Co., Ltd. announced today that it has entered into an agreement with Shanghai Wan'Te Pharmaceutical Co., Ltd. to acquire the intellectual property, exclusive sales and manufacturing rights of micro-emulsion alprostadil injection from Wan'Te for total proceeds of RMB10 million, of which RMB5 million will be paid in cash and RMB5 million will be paid in shares of the Company's common stock.
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas.
Remote Diagnostic Technologies Ltd., an innovator in pre-hospital care, today announced the launch of its Tempus ALS monitor and defibrillator at the Emergency Services Show in Birmingham. Lighter and more focused than existing technologies, the Tempus ALS enables paramedics to carry less and do much more.
HDL is the 'good cholesterol' that helps remove fat from artery walls, reversing the process that leads to heart disease. Yet recent drug trials and genetic studies suggest that simply pushing HDL levels higher doesn't necessarily reduce the risk of heart disease.
› Verified 1 days ago
Anthony J Kazlauskas, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 11 Carnival Ter, West Warwick, RI 02893 Phone: 401-615-3225 Fax: 401-732-7192 | |
Dr. Katherine M Sharkey, MD, PH.D Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1 James P Murphy Ind Hwy, West Warwick, RI 02893 Phone: 401-615-5878 Fax: 401-615-5886 | |
Dr. Max Reed Cohen, DO Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 1079 Main St Ste A, West Warwick, RI 02893 Phone: 401-828-2663 Fax: 401-822-0490 | |
Michael T Poshkus, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 186 Providence St, West Warwick, RI 02893 Phone: 401-615-2800 Fax: 401-615-2805 |